glp-1 agonists and health coaching Agonists: Using Semaglutide, Tirzepatide, Orforglipron for Weight Loss and Obesity Impact of GLP- 1 Receptor

As the obesity epidemic fuels demand for these new drugs, Lilly looks set to retain its lead, unless a competitor can outpace its innovation and commercialization in the GLP-1 field

The demographic distribution of those most likely to stop treatment was as follows: patients of color, men, people enrolled in Medicare or Medicaid, those living in areas with very high social needs, heart failure, obesity or other cardiovascular diseases prior to drug initiation, and those experiencing new gastrointestinal adverse effects at follow-up [132]

Increasing the dose may produce additional weight loss, but it also increases side effects and cost

They need a simple way to see whether low-hunger days, water intake, protein, constipation, fatigue, cycle notes, and the scale are moving together or pulling in different directions

The message is simple: Take this shot and the weight will disappear

A patient of mine, a veteran who had tried to quit smoking for over a decade, told me that after he started a GLP-1 drug for his diabetes, he lost interest in cigarettes